Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
McKesson
Medtronic
Express Scripts

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ILOPROST

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Iloprost

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004786 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed University of Pittsburgh Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00004786 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed National Center for Research Resources (NCRR) Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00084409 Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease Completed National Cancer Institute (NCI) Phase 2 2001-11-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iloprost

Condition Name

Condition Name for Iloprost
Intervention Trials
Pulmonary Hypertension 22
Pulmonary Arterial Hypertension 18
Hypertension, Pulmonary 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Iloprost
Intervention Trials
Hypertension 51
Hypertension, Pulmonary 33
Familial Primary Pulmonary Hypertension 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Iloprost

Trials by Country

Trials by Country for Iloprost
Location Trials
United States 196
Germany 39
China 14
Japan 11
France 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Iloprost
Location Trials
California 16
New York 11
Pennsylvania 11
Texas 11
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Iloprost

Clinical Trial Phase

Clinical Trial Phase for Iloprost
Clinical Trial Phase Trials
Phase 4 17
Phase 3 15
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Iloprost
Clinical Trial Phase Trials
Completed 35
Terminated 13
Unknown status 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Iloprost

Sponsor Name

Sponsor Name for Iloprost
Sponsor Trials
Actelion 17
Bayer 16
University of Chicago 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Iloprost
Sponsor Trials
Other 70
Industry 41
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Merck
AstraZeneca
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.